img

Global Non-infectious Macular Edema Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034


Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Non-infectious Macular Edema Treatment Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Non-infectious Macular Edema Treatment refers to the treatment of Non-infectious Macular Edema by drugs or therapies such as anti-VEGF therapy, corticosteroids, immunosuppressive agents, and biological agents. The macula is a region of the center of the retina. Macular edema is the accumulation of fluid in the macula that causes the macula to swell and thicken, thereby distorting vision.
Due to the COVID-19 pandemic, the global Non-infectious Macular Edema Treatment market size was US$ 10840 million in 2022 and is forecast to a readjusted size of US$ 15240 million by 2034 with a CAGR of 4.9% during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Anti-VEGF Therapy accounting for % of the Non-infectious Macular Edema Treatment global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Retail Pharmacy segment is altered to an % CAGR throughout this forecast period.
The global key companies of Non-infectious Macular Edema Treatment include Allergan, Amgen, Pfizer, Novartis AG, F. Hoffman-La Roche, AbbVie, Bayer AG, Valeant Pharmaceuticals and Alimera Sciences, etc. In 2022, the global top five players had a share approximately % in terms of revenue.
The United States Non-infectious Macular Edema Treatment market size was US$ million in 2022, while China size was US$ million. The proportion of the United States was % in 2022, while China percentage was %, and it is predicted that China share will reach % in 2034, trailing a CAGR of % through the analysis period. As for the Europe Non-infectious Macular Edema Treatment landscape, Germany is projected to reach US$ million by 2034. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Non-infectious Macular Edema Treatment market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Non-infectious Macular Edema Treatment market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Non-infectious Macular Edema Treatment market. Readers of the report can become informed about current and future trends of the global Non-infectious Macular Edema Treatment market and how they will impact market growth during the forecast period.



By Company


Allergan
Amgen
Pfizer
Novartis AG
F. Hoffman-La Roche
AbbVie
Bayer AG
Valeant Pharmaceuticals
Alimera Sciences
Clearside Biomedical
Segment by Type
Anti-VEGF Therapy
Corticosteroid
Immune Inhibitor
Biological Preparation
Other

Segment by Application


Retail Pharmacy
Hospital Pharmacy
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Non-infectious Macular Edema Treatment in global and regional level.
Chapter 3Detailed analysis of Non-infectious Macular Edema Treatment companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Non-infectious Macular Edema Treatment revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-infectious Macular Edema Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2034
1.2.2 Anti-VEGF Therapy
1.2.3 Corticosteroid
1.2.4 Immune Inhibitor
1.2.5 Biological Preparation
1.2.6 Other
1.3 Market by Application
1.3.1 Global Non-infectious Macular Edema Treatment Market Growth Rate by Application: 2018 VS 2022 VS 2034
1.3.2 Retail Pharmacy
1.3.3 Hospital Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Market Perspective
2.1 Global Non-infectious Macular Edema Treatment Market Size (2018-2034)
2.2 Non-infectious Macular Edema Treatment Market Size across Key Geographies Worldwide: 2018 VS 2022 VS 2034
2.3 Global Non-infectious Macular Edema Treatment Market Size by Region (2018-2024)
2.4 Global Non-infectious Macular Edema Treatment Market Size Forecast by Region (2024-2034)
2.5 Global Top 10 Non-infectious Macular Edema Treatment Countries Ranking by Market Size
3 Non-infectious Macular Edema Treatment Competitive by Company
3.1 Global Non-infectious Macular Edema Treatment Revenue by Players
3.1.1 Global Non-infectious Macular Edema Treatment Revenue by Players (2018-2024)
3.1.2 Global Non-infectious Macular Edema Treatment Market Share by Players (2018-2024)
3.2 Global Non-infectious Macular Edema Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Company Covered: Ranking by Non-infectious Macular Edema Treatment Revenue
3.4 Global Non-infectious Macular Edema Treatment Market Concentration Ratio
3.4.1 Global Non-infectious Macular Edema Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-infectious Macular Edema Treatment Revenue in 2022
3.5 Global Key Players of Non-infectious Macular Edema Treatment Head office and Area Served
3.6 Global Key Players of Non-infectious Macular Edema Treatment, Product and Application
3.7 Global Key Players of Non-infectious Macular Edema Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Global Non-infectious Macular Edema Treatment Breakdown Data by Type
4.1 Global Non-infectious Macular Edema Treatment Historic Revenue by Type (2018-2024)
4.2 Global Non-infectious Macular Edema Treatment Forecasted Revenue by Type (2024-2034)
5 Global Non-infectious Macular Edema Treatment Breakdown Data by Application
5.1 Global Non-infectious Macular Edema Treatment Historic Market Size by Application (2018-2024)
5.2 Global Non-infectious Macular Edema Treatment Forecasted Market Size by Application (2024-2034)
6 North America
6.1 North America Non-infectious Macular Edema Treatment Revenue by Company (2021-2024)
6.2 North America Non-infectious Macular Edema Treatment Revenue by Type (2018-2034)
6.3 North America Non-infectious Macular Edema Treatment Revenue by Application (2018-2034)
6.4 North America Non-infectious Macular Edema Treatment Revenue by Country (2018-2034)
6.4.1 U.S.
6.4.2 Canada
7 Europe
7.1 Europe Non-infectious Macular Edema Treatment Revenue by Company (2021-2024)
7.2 Europe Non-infectious Macular Edema Treatment Revenue by Type (2018-2034)
7.3 Europe Non-infectious Macular Edema Treatment Revenue by Application (2018-2034)
7.4 Europe Non-infectious Macular Edema Treatment Revenue by Country (2018-2034)
7.4.1 Germany
7.4.2 France
7.4.3 U.K.
7.4.4 Italy
7.4.5 Russia
8 Asia Pacific
8.1 Asia Pacific Non-infectious Macular Edema Treatment Revenue by Company (2021-2024)
8.2 Asia Pacific Non-infectious Macular Edema Treatment Revenue by Type (2018-2034)
8.3 Asia Pacific Non-infectious Macular Edema Treatment Revenue by Application (2018-2034)
8.4 Asia Pacific Non-infectious Macular Edema Treatment Revenue by Region (2018-2034)
8.4.1 China
8.4.2 Japan
8.4.3 South Korea
8.4.4 India
8.4.5 Australia
8.4.6 Taiwan
8.4.7 Indonesia
8.4.8 Thailand
8.4.9 Malaysia
8.4.10 Philippines
8.4.11 Vietnam
9 Latin America
9.1 Latin America Non-infectious Macular Edema Treatment Revenue by Company (2021-2024)
9.2 Latin America Non-infectious Macular Edema Treatment Revenue by Type (2018-2034)
9.3 Latin America Non-infectious Macular Edema Treatment Revenue by Application (2018-2034)
9.4 Latin America Non-infectious Macular Edema Treatment Revenue by Country (2018-2034)
9.4.1 Mexico
9.4.2 Brazil
9.4.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Company (2021-2024)
10.2 Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Type (2018-2034)
10.3 Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Application (2018-2034)
10.4 Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Country (2018-2034)
10.4.1 Turkey
10.4.2 Saudi Arabia
10.4.3 U.A.E
11 Company Profiles
11.1 Allergan
11.1.1 Allergan Company Details
11.1.2 Allergan Business Overview
11.1.3 Allergan Non-infectious Macular Edema Treatment Products and Services
11.1.4 Allergan Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024)
11.1.5 Allergan Non-infectious Macular Edema Treatment SWOT Analysis
11.1.6 Allergan Recent Development
11.2 Amgen
11.2.1 Amgen Company Details
11.2.2 Amgen Business Overview
11.2.3 Amgen Non-infectious Macular Edema Treatment Products and Services
11.2.4 Amgen Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024)
11.2.5 Amgen Non-infectious Macular Edema Treatment SWOT Analysis
11.2.6 Amgen Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Details
11.3.2 Pfizer Business Overview
11.3.3 Pfizer Non-infectious Macular Edema Treatment Products and Services
11.3.4 Pfizer Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024)
11.3.5 Pfizer Non-infectious Macular Edema Treatment SWOT Analysis
11.3.6 Pfizer Recent Development
11.4 Novartis AG
11.4.1 Novartis AG Company Details
11.4.2 Novartis AG Business Overview
11.4.3 Novartis AG Non-infectious Macular Edema Treatment Products and Services
11.4.4 Novartis AG Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024)
11.4.5 Novartis AG Non-infectious Macular Edema Treatment SWOT Analysis
11.4.6 Novartis AG Recent Development
11.5 F. Hoffman-La Roche
11.5.1 F. Hoffman-La Roche Company Details
11.5.2 F. Hoffman-La Roche Business Overview
11.5.3 F. Hoffman-La Roche Non-infectious Macular Edema Treatment Products and Services
11.5.4 F. Hoffman-La Roche Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024)
11.5.5 F. Hoffman-La Roche Non-infectious Macular Edema Treatment SWOT Analysis
11.5.6 F. Hoffman-La Roche Recent Development
11.6 AbbVie
11.6.1 AbbVie Company Details
11.6.2 AbbVie Business Overview
11.6.3 AbbVie Non-infectious Macular Edema Treatment Products and Services
11.6.4 AbbVie Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024)
11.6.5 AbbVie Non-infectious Macular Edema Treatment SWOT Analysis
11.6.6 AbbVie Recent Development
11.7 Bayer AG
11.7.1 Bayer AG Company Details
11.7.2 Bayer AG Business Overview
11.7.3 Bayer AG Non-infectious Macular Edema Treatment Products and Services
11.7.4 Bayer AG Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024)
11.7.5 Bayer AG Non-infectious Macular Edema Treatment SWOT Analysis
11.7.6 Bayer AG Recent Development
11.8 Valeant Pharmaceuticals
11.8.1 Valeant Pharmaceuticals Company Details
11.8.2 Valeant Pharmaceuticals Business Overview
11.8.3 Valeant Pharmaceuticals Non-infectious Macular Edema Treatment Products and Services
11.8.4 Valeant Pharmaceuticals Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024)
11.8.5 Valeant Pharmaceuticals Non-infectious Macular Edema Treatment SWOT Analysis
11.8.6 Valeant Pharmaceuticals Recent Development
11.9 Alimera Sciences
11.9.1 Alimera Sciences Company Details
11.9.2 Alimera Sciences Business Overview
11.9.3 Alimera Sciences Non-infectious Macular Edema Treatment Products and Services
11.9.4 Alimera Sciences Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024)
11.9.5 Alimera Sciences Non-infectious Macular Edema Treatment SWOT Analysis
11.9.6 Alimera Sciences Recent Development
11.10 Clearside Biomedical
11.10.1 Clearside Biomedical Company Details
11.10.2 Clearside Biomedical Business Overview
11.10.3 Clearside Biomedical Non-infectious Macular Edema Treatment Products and Services
11.10.4 Clearside Biomedical Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024)
11.10.5 Clearside Biomedical Non-infectious Macular Edema Treatment SWOT Analysis
11.10.6 Clearside Biomedical Recent Development
12 Non-infectious Macular Edema Treatment Market Dynamics
12.1 Non-infectious Macular Edema Treatment Industry Trends
12.2 Non-infectious Macular Edema Treatment Market Drivers
12.3 Non-infectious Macular Edema Treatment Market Challenges
12.4 Non-infectious Macular Edema Treatment Market Restraints
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details

List of Figure

List of Tables
Table 1. Global Non-infectious Macular Edema Treatment Market Size Growth Rate (CAGR) by Type (US$ Million), 2018 VS 2022 VS 2034
Table 2. Key Players of Anti-VEGF Therapy
Table 3. Key Players of Corticosteroid
Table 4. Key Players of Immune Inhibitor
Table 5. Key Players of Biological Preparation
Table 6. Key Players of Other
Table 7. Global Non-infectious Macular Edema Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2034
Table 8. Global Non-infectious Macular Edema Treatment Market Size (US$ Million) Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2034
Table 9. Global Non-infectious Macular Edema Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 10. Global Non-infectious Macular Edema Treatment Revenue Forecast by Region (2024-2034) & (US$ Million)
Table 11. Global Non-infectious Macular Edema Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Table 12. Global Non-infectious Macular Edema Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 13. Global Non-infectious Macular Edema Treatment Market Share by Players (2018-2024)
Table 14. Global Top Non-infectious Macular Edema Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-infectious Macular Edema Treatment as of 2022)
Table 15. Ranking of Global Top Non-infectious Macular Edema Treatment Companies by Revenue (US$ Million) in 2022
Table 16. Global 5 Largest Players Market Share by Non-infectious Macular Edema Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 17. Global Key Players of Non-infectious Macular Edema Treatment, Headquarters and Area Served
Table 18. Global Key Players of Non-infectious Macular Edema Treatment, Product and Application
Table 19. Global Key Players of Non-infectious Macular Edema Treatment, Date of Enter into This Industry
Table 20. Mergers & Acquisitions, Expansion Plans
Table 21. Global Non-infectious Macular Edema Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 22. Global Non-infectious Macular Edema Treatment Revenue Market Share by Type (2018-2024)
Table 23. Global Non-infectious Macular Edema Treatment Forecasted Market Size by Type (2024-2034) & (US$ Million)
Table 24. Global Non-infectious Macular Edema Treatment Revenue Market Share by Type (2024-2034)
Table 25. Global Non-infectious Macular Edema Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 26. Global Non-infectious Macular Edema Treatment Revenue Market Share by Application (2018-2024)
Table 27. Global Non-infectious Macular Edema Treatment Forecasted Market Size by Application (2024-2034) & (US$ Million)
Table 28. Global Non-infectious Macular Edema Treatment Revenue Market Share by Application (2024-2034)
Table 29. North America Non-infectious Macular Edema Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 30. North America Non-infectious Macular Edema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 31. North America Non-infectious Macular Edema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 32. North America Non-infectious Macular Edema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 33. North America Non-infectious Macular Edema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 34. North America Non-infectious Macular Edema Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 35. North America Non-infectious Macular Edema Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 36. North America Non-infectious Macular Edema Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 37. Europe Non-infectious Macular Edema Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 38. Europe Non-infectious Macular Edema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 39. Europe Non-infectious Macular Edema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 40. Europe Non-infectious Macular Edema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 41. Europe Non-infectious Macular Edema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 42. Europe Non-infectious Macular Edema Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 43. Europe Non-infectious Macular Edema Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 44. Europe Non-infectious Macular Edema Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 45. Asia Pacific Non-infectious Macular Edema Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 46. Asia Pacific Non-infectious Macular Edema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 47. Asia Pacific Non-infectious Macular Edema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 48. Asia Pacific Non-infectious Macular Edema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 49. Asia Pacific Non-infectious Macular Edema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 50. Asia-Pacific Non-infectious Macular Edema Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2034
Table 51. Asia Pacific Non-infectious Macular Edema Treatment Revenue by Region (2018-2024) & (US$ Million)
Table 52. Asia Pacific Non-infectious Macular Edema Treatment Revenue by Region (2024-2034) & (US$ Million)
Table 53. Latin America Non-infectious Macular Edema Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 54. Latin America Non-infectious Macular Edema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 55. Latin America Non-infectious Macular Edema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 56. Latin America Non-infectious Macular Edema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 57. Latin America Non-infectious Macular Edema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 58. Latin America Non-infectious Macular Edema Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 59. Latin America Non-infectious Macular Edema Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 60. Latin America Non-infectious Macular Edema Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 61. Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Company (2021-2024) & (US$ Million)
Table 62. Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Type (2018-2024) & (US$ Million)
Table 63. Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Type (2024-2034) & (US$ Million)
Table 64. Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Application (2018-2024) & (US$ Million)
Table 65. Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Application (2024-2034) & (US$ Million)
Table 66. Middle East and Africa Non-infectious Macular Edema Treatment Revenue Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2034
Table 67. Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Country (2018-2024) & (US$ Million)
Table 68. Middle East and Africa Non-infectious Macular Edema Treatment Revenue by Country (2024-2034) & (US$ Million)
Table 69. Allergan Company Details
Table 70. Allergan Business Overview
Table 71. Allergan Non-infectious Macular Edema Treatment Product and Services
Table 72. Allergan Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024) & (US$ Million)
Table 73. Allergan Non-infectious Macular Edema Treatment SWOT Analysis
Table 74. Allergan Recent Development
Table 75. Amgen Company Details
Table 76. Amgen Business Overview
Table 77. Amgen Non-infectious Macular Edema Treatment Product and Services
Table 78. Amgen Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024) & (US$ Million)
Table 79. Amgen Non-infectious Macular Edema Treatment SWOT Analysis
Table 80. Amgen Recent Development
Table 81. Pfizer Company Details
Table 82. Pfizer Business Overview
Table 83. Pfizer Non-infectious Macular Edema Treatment Product and Services
Table 84. Pfizer Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024) & (US$ Million)
Table 85. Pfizer Non-infectious Macular Edema Treatment SWOT Analysis
Table 86. Pfizer Recent Development
Table 87. Novartis AG Company Details
Table 88. Novartis AG Business Overview
Table 89. Novartis AG Non-infectious Macular Edema Treatment Product and Services
Table 90. Novartis AG Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024) & (US$ Million)
Table 91. Novartis AG Non-infectious Macular Edema Treatment SWOT Analysis
Table 92. Novartis AG Recent Development
Table 93. F. Hoffman-La Roche Company Details
Table 94. F. Hoffman-La Roche Business Overview
Table 95. F. Hoffman-La Roche Non-infectious Macular Edema Treatment Product and Services
Table 96. F. Hoffman-La Roche Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024) & (US$ Million)
Table 97. F. Hoffman-La Roche Non-infectious Macular Edema Treatment SWOT Analysis
Table 98. F. Hoffman-La Roche Recent Development
Table 99. AbbVie Company Details
Table 100. AbbVie Business Overview
Table 101. AbbVie Non-infectious Macular Edema Treatment Product and Services
Table 102. AbbVie Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024) & (US$ Million)
Table 103. AbbVie Non-infectious Macular Edema Treatment SWOT Analysis
Table 104. AbbVie Recent Development
Table 105. Bayer AG Company Details
Table 106. Bayer AG Business Overview
Table 107. Bayer AG Non-infectious Macular Edema Treatment Product and Services
Table 108. Bayer AG Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024) & (US$ Million)
Table 109. Bayer AG Non-infectious Macular Edema Treatment SWOT Analysis
Table 110. Bayer AG Recent Development
Table 111. Valeant Pharmaceuticals Company Details
Table 112. Valeant Pharmaceuticals Business Overview
Table 113. Valeant Pharmaceuticals Non-infectious Macular Edema Treatment Product and Services
Table 114. Valeant Pharmaceuticals Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024) & (US$ Million)
Table 115. Valeant Pharmaceuticals Non-infectious Macular Edema Treatment SWOT Analysis
Table 116. Valeant Pharmaceuticals Recent Development
Table 117. Alimera Sciences Company Details
Table 118. Alimera Sciences Business Overview
Table 119. Alimera Sciences Non-infectious Macular Edema Treatment Product and Services
Table 120. Alimera Sciences Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024) & (US$ Million)
Table 121. Alimera Sciences Non-infectious Macular Edema Treatment SWOT Analysis
Table 122. Alimera Sciences Recent Development
Table 123. Clearside Biomedical Company Details
Table 124. Clearside Biomedical Business Overview
Table 125. Clearside Biomedical Non-infectious Macular Edema Treatment Product and Services
Table 126. Clearside Biomedical Non-infectious Macular Edema Treatment Revenue in Non-infectious Macular Edema Treatment Business (2018-2024) & (US$ Million)
Table 127. Clearside Biomedical Non-infectious Macular Edema Treatment SWOT Analysis
Table 128. Clearside Biomedical Recent Development
Table 129. Non-infectious Macular Edema Treatment Market Trends
Table 130. Non-infectious Macular Edema Treatment Market Drivers
Table 131. Non-infectious Macular Edema Treatment Market Challenges
Table 132. Non-infectious Macular Edema Treatment Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
List of Figures
Figure 1. Non-infectious Macular Edema Treatment Product Picture
Figure 2. Global Non-infectious Macular Edema Treatment Market Size by Type (US$ Million): 2018 VS 2022 VS 2034
Figure 3. Global Non-infectious Macular Edema Treatment Market Share by Type: 2022 VS 2034
Figure 4. Anti-VEGF Therapy Features
Figure 5. Corticosteroid Features
Figure 6. Immune Inhibitor Features
Figure 7. Biological Preparation Features
Figure 8. Other Features
Figure 9. Global Non-infectious Macular Edema Treatment Market Size by Application (US$ Million): 2018 VS 2022 VS 2034
Figure 10. Global Non-infectious Macular Edema Treatment Market Share by Application: 2022 VS 2034
Figure 11. Retail Pharmacy
Figure 12. Hospital Pharmacy
Figure 13. Other
Figure 14. Non-infectious Macular Edema Treatment Report Years Considered
Figure 15. Global Non-infectious Macular Edema Treatment Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 16. Global Non-infectious Macular Edema Treatment Market Size 2018-2034 (US$ Million)
Figure 17. Global Non-infectious Macular Edema Treatment Market Size Market Share by Region: 2022 VS 2034
Figure 18. Global Non-infectious Macular Edema Treatment Revenue Market Share by Region in 2018 VS 2022
Figure 19. Global Non-infectious Macular Edema Treatment Revenue Market Share Forecast by Region (2024-2034)
Figure 20. Global Top 10 Non-infectious Macular Edema Treatment Countries Ranking by Market Size (US$ Million) in 2022
Figure 21. Global Non-infectious Macular Edema Treatment Market Size of Top 10 Countries, 2018 VS 2022 VS 2034, (US$ Million)
Figure 22. Global Non-infectious Macular Edema Treatment Market Share by Players in 2022
Figure 23. Global Top Non-infectious Macular Edema Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-infectious Macular Edema Treatment as of 2022)
Figure 24. The Top 10 and 5 Players Market Share by Non-infectious Macular Edema Treatment Revenue in 2022
Figure 25. North America Non-infectious Macular Edema Treatment Revenue Market Share by Company in 2022
Figure 26. North America Non-infectious Macular Edema Treatment Revenue Market Share by Type (2018-2034)
Figure 27. North America Non-infectious Macular Edema Treatment Revenue Market Share by Application (2018-2034)
Figure 28. North America Non-infectious Macular Edema Treatment Revenue Share by Country (2018-2034)
Figure 29. U.S. Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 30. Canada Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 31. Europe Non-infectious Macular Edema Treatment Revenue Market Share by Company in 2022
Figure 32. Europe Non-infectious Macular Edema Treatment Revenue Market Share by Type (2018-2034)
Figure 33. Europe Non-infectious Macular Edema Treatment Revenue Market Share by Application (2018-2034)
Figure 34. Europe Non-infectious Macular Edema Treatment Revenue Share by Country (2018-2034)
Figure 35. Germany Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 36. France Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 37. U.K. Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 38. Italy Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 39. Russia Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 40. Asia Pacific Non-infectious Macular Edema Treatment Revenue Market Share by Company in 2022
Figure 41. Asia Pacific Non-infectious Macular Edema Treatment Revenue Market Share by Type (2018-2034)
Figure 42. Asia Pacific Non-infectious Macular Edema Treatment Revenue Market Share by Application (2018-2034)
Figure 43. Asia Pacific Non-infectious Macular Edema Treatment Revenue Share by Region (2018-2034)
Figure 44. China Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 45. Japan Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 46. South Korea Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 47. India Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 48. Australia Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 49. Taiwan Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 50. Indonesia Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 51. Thailand Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 52. Malaysia Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 53. Philippines Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 54. Vietnam Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 55. Latin America Non-infectious Macular Edema Treatment Revenue Market Share by Company in 2022
Figure 56. Latin America Non-infectious Macular Edema Treatment Revenue Market Share by Type (2018-2034)
Figure 57. Latin America Non-infectious Macular Edema Treatment Revenue Market Share by Application (2018-2034)
Figure 58. Latin America Non-infectious Macular Edema Treatment Revenue Share by Country (2018-2034)
Figure 59. Mexico Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 60. Brazil Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 61. Argentina Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 62. Middle East and Africa Non-infectious Macular Edema Treatment Revenue Market Share by Company in 2022
Figure 63. Middle East and Africa Non-infectious Macular Edema Treatment Revenue Market Share by Type (2018-2034)
Figure 64. Middle East and Africa Non-infectious Macular Edema Treatment Revenue Market Share by Application (2018-2034)
Figure 65. Middle East and Africa Non-infectious Macular Edema Treatment Revenue Share by Country (2018-2034)
Figure 66. Turkey Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 67. Saudi Arabia Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 68. U.A.E Non-infectious Macular Edema Treatment Revenue (2018-2034) & (US$ Million)
Figure 69. Allergan Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2024)
Figure 70. Amgen Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2024)
Figure 71. Pfizer Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2024)
Figure 72. Novartis AG Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2024)
Figure 73. F. Hoffman-La Roche Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2024)
Figure 74. AbbVie Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2024)
Figure 75. Bayer AG Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2024)
Figure 76. Valeant Pharmaceuticals Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2024)
Figure 77. Alimera Sciences Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2024)
Figure 78. Clearside Biomedical Revenue Growth Rate in Non-infectious Macular Edema Treatment Business (2018-2024)
Figure 79. Bottom-up and Top-down Approaches for This Report
Figure 80. Data Triangulation
Figure 81. Key Executives Interviewed